Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

SODIUM PHENYLBUTYRATE IMPURITY C CRS (10 MG)

SODIUM PHENYLBUTYRATE IMPURITY C CRS (10 MG)

4441-63-8

DISCOVER
ACEMETACIN CRS (100 MG)

ACEMETACIN CRS (100 MG)

53164-05-9

DISCOVER
ACEMETACIN IMPURITY A CRS (20MG)

ACEMETACIN IMPURITY A CRS (20MG)

74-11-3

DISCOVER
BISOPROLOL FUMARATE CRS (50 MG)

BISOPROLOL FUMARATE CRS (50 MG)

104344-23-2

DISCOVER
BISOPROLOL FOR SYSTEM SUITABILITY CRS (1.003 MG)

BISOPROLOL FOR SYSTEM SUITABILITY CRS (1.003 MG)

104344-23-2

DISCOVER
SELAMECTIN CRS (120 MG)

SELAMECTIN CRS (120 MG)

165108-07-6

DISCOVER
ATROPINE IMPURITY B CRS (15 MG)

ATROPINE IMPURITY B CRS (15 MG)

NA

DISCOVER
CLOTRIMAZOLE IMPURITY E CRS (15 MG)

CLOTRIMAZOLE IMPURITY E CRS (15 MG)

08/03/5162

DISCOVER
MARBOFLOXACIN CRS (10 MG)

MARBOFLOXACIN CRS (10 MG)

115550-35-1

DISCOVER
Marbofloxacin for peak identification CRS, 20mg

Marbofloxacin for peak identification CRS, 20mg

115550-35-1

DISCOVER
MOLSIDOMINE CRS (5 MG)

MOLSIDOMINE CRS (5 MG)

25717-80-0

DISCOVER
MOLSIDOMINE IMPURITY B CRS (10 MG)

MOLSIDOMINE IMPURITY B CRS (10 MG)

59-89-2

DISCOVER